Referral for cancer genetics consultation: a review and compilation of risk assessment criteria

Background: There have been many papers on the diagnostic criteria for specific hereditary cancer susceptibility syndromes and the likelihood that an individual has a germline mutation in one of the various cancer susceptibility genes. To assist health care professionals in deciding when a cancer genetics consultation is appropriate, available reports were critically reviewed in order to develop a single set of risk assessment criteria. Methods: The criteria were based on a comprehensive review of publications describing diagnostic criteria for hereditary cancer syndromes and risk to first degree relatives of cancer patients. Priority was given to diagnostic criteria from consensus statements (for example, those from the National Comprehensive Cancer Network). Expert opinion from study personnel was then used to adopt a single set of criteria from other publications whenever guidelines differed. Results: Based on family history, a set of criteria was developed to identify patients at risk for a hereditary cancer susceptibility syndrome, patients with moderate risk who might benefit from increased cancer surveillance, and patients who are at average risk. The criteria were applied to 4360 individuals who provided their cancer family history between July 1999 and April 2002, using a touch screen computer system in the lobby of a comprehensive cancer centre. They categorised an acceptable number of users into each risk level: 14.9% high risk, 13.7% moderate risk, and 59.6% average risk; 11.8% provided insufficient information for risk assessment. Conclusions: These criteria should improve ease of referral and promote consistency across centres when evaluating patients for referral to cancer genetics specialists.

[1]  J. Strauchen Germ-line mutations in nonsyndromic pheochromocytoma. , 2002, The New England journal of medicine.

[2]  J. Schipper,et al.  Germ-line mutations in nonsyndromic pheochromocytoma. , 2002, The New England journal of medicine.

[3]  K. Klinger,et al.  Germline mutations in the ribonuclease L gene in families showing linkage with HPC1 , 2002, Nature Genetics.

[4]  K. Calzone,et al.  Genetic Testing for Cancer Predisposition , 2002, Cancer nursing.

[5]  K. Sweet,et al.  Identification and referral of families at high risk for cancer susceptibility. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Ostrander,et al.  Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations inBRCA1 , 2001, Journal of medical genetics.

[7]  W. Zoller,et al.  [Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer]. , 2001, Zeitschrift fur Gastroenterologie.

[8]  W. Rubinstein,et al.  Proportion of Heritable Paraganglioma Cases and Associated Clinical Characteristics , 2001, The Laryngoscope.

[9]  J. Emery,et al.  Common hereditary cancers and implications for primary care , 2001, The Lancet.

[10]  C. Eng Will the real Cowden syndrome please stand up: revised diagnostic criteria , 2000, Journal of medical genetics.

[11]  L A Kalish,et al.  Family history and the risk of prostate cancer. , 2000, Urology.

[12]  T. Rebbeck,et al.  Association of HPC2/ELAC2 genotypes and prostate cancer. , 2000, American journal of human genetics.

[13]  N. Gruis,et al.  Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16‐Leiden) , 2000, International journal of cancer.

[14]  Charis Eng,et al.  Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations inMSH2 and MLH1 , 2000, Journal of medical genetics.

[15]  L. Aaltonen,et al.  Population-based molecular detection of hereditary nonpolyposis colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  E. Ostrander,et al.  Frequency of BRCA1/BRCA2 mutations in a population‐based sample of young breast carcinoma cases , 2000, Cancer.

[17]  B. Weber,et al.  Assessing the risk of breast cancer. , 2000, The New England journal of medicine.

[18]  R. Thakker,et al.  Multiple endocrine neoplasia type 1. , 1999, Endocrine-related cancer.

[19]  M. Tucker,et al.  Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Evans,et al.  Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. , 1999, American journal of human genetics.

[21]  Nazneen,et al.  Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.

[22]  H T Lynch,et al.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. , 1999, Gastroenterology.

[23]  E. Goode,et al.  Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. , 1999, American journal of human genetics.

[24]  J. Mulvihill,et al.  The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. , 1998, Surgery.

[25]  F. Collins,et al.  Evidence for a prostate cancer susceptibility locus on the X chromosome. , 1998, Nature Genetics.

[26]  W. Vogel,et al.  Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. , 1998, American journal of human genetics.

[27]  L. Aaltonen,et al.  Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. , 1998, The New England journal of medicine.

[28]  M. Tucker,et al.  CDKN2A mutations in multiple primary melanomas. , 1998, The New England journal of medicine.

[29]  C. Boland,et al.  A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. , 1997, Journal of the National Cancer Institute.

[30]  D. Schaid Re: probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. , 1997, Journal of the National Cancer Institute.

[31]  K Offit,et al.  BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. , 1997, JAMA.

[32]  D. Evans,et al.  Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. , 1997, Cancer research.

[33]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[34]  F. Couch,et al.  BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. , 1997, The New England journal of medicine.

[35]  M. Skolnick,et al.  Genetic susceptibility to breast and ovarian cancer. , 1997, Pathologie-biologie.

[36]  D. Berry,et al.  Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. , 1997, Journal of the National Cancer Institute.

[37]  D A Meyers,et al.  Major Susceptibility Locus for Prostate Cancer on Chromosome 1 Suggested by a Genome-Wide Search , 1996, Science.

[38]  P. Ganz,et al.  Agreement between breast cancer risk estimation methods. , 1996, Journal of the National Cancer Institute.

[39]  A M Goldstein,et al.  Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. , 1995, The New England journal of medicine.

[40]  S. Franceschi,et al.  Risk of cutaneous melanoma associated with a family history of the disease , 1995, International journal of cancer.

[41]  B. Ponder,et al.  Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma , 1995, Genes, chromosomes & cancer.

[42]  R. Hayes,et al.  Prostate cancer risk in U.S. blacks and whites with a family history of cancer , 1995, International journal of cancer.

[43]  C. Portwine,et al.  High frequency of germline p53 mutations in childhood adrenocortical cancer. , 1994, Journal of the National Cancer Institute.

[44]  M H Skolnick,et al.  Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. , 1994, Journal of the National Cancer Institute.

[45]  A. Craft,et al.  Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. , 1994, Cancer research.

[46]  N Risch,et al.  Autosomal dominant inheritance of early‐onset breast cancer. Implications for risk prediction , 1994, Cancer.

[47]  N. Risch,et al.  The calculation of breast cancer risk for women with a first degree family history of ovarian cancer , 1993, Breast Cancer Research and Treatment.

[48]  J. Benichou A computer program for estimating individualized probabilities of breast cancer. , 1993, Computers and biomedical research, an international journal.

[49]  J. Birch,et al.  Patterns of cancer in the families of children with soft tissue sarcoma , 1993, Cancer.

[50]  D. S. St. John,et al.  Cancer Risk in Relatives of Patients with Common Colorectal Cancer , 1993, Annals of Internal Medicine.

[51]  K. Kerlikowske,et al.  Should women with familial ovarian cancer undergo prophylactic oophorectomy? , 1992, Obstetrics and gynecology.

[52]  J. Fraumeni,et al.  Follow-up study of twenty-four families with Li-Fraumeni syndrome. , 1991, Cancer research.

[53]  M. Spitz,et al.  Familial patterns of prostate cancer: a case-control analysis. , 1991, The Journal of urology.

[54]  J. Mecklin,et al.  The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) , 1991, Diseases of the colon and rectum.

[55]  P. H. Jones,et al.  Cancer in the families of children with soft tissue sarcoma , 1990, Cancer.

[56]  R. Houlston,et al.  Screening and genetic counselling for relatives of patients with colorectal cancer in a family cancer clinic. , 1990, BMJ.

[57]  M. Gail,et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.

[58]  W. Blattner,et al.  A cancer family syndrome in twenty-four kindreds. , 1988, Cancer research.

[59]  J. Fraumeni,et al.  A population-based case-control study of thyroid cancer. , 1987, Journal of the National Cancer Institute.

[60]  C. M. Woolf An investigation of the familial aspects of carcinoma of the prostate , 1960, Cancer.

[61]  American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing. , 2001, Gastroenterology.

[62]  J Benichou,et al.  Graphs to estimate an individualized risk of breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  R. Eeles Predictive testing for germline mutations in the p53 gene: are all the questions answered? , 1993, European journal of cancer.

[65]  Susan E. Kutner Breast cancer genetics and managed care , 2022 .